Open label, long-term, pragmatic study on levetiracetam in the treatment of juvenile myoclonic epilepsy
- 1 September 2006
- journal article
- clinical trial
- Published by Elsevier in Epilepsy Research
- Vol. 71 (1) , 32-39
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Levetiracetam Reduces Spike–Wave Density and Duration during Continuous EEG Monitoring in Patients with Idiopathic Generalized EpilepsyEpilepsia, 2003
- Clinical factors of drug resistance in juvenile myoclonic epilepsyJournal of Neurology, Neurosurgery & Psychiatry, 2001
- Treatment of Typical Absence Seizures and Related Epileptic SyndromesPediatric Drugs, 2001
- Efficacy and Tolerability of Levetiracetam 3000 mg/d in Patients with Refractory Partial Seizures: A Multicenter, Double‐Blind, Responder‐Selected Study Evaluating MonotherapyEpilepsia, 2000
- Multicenter Double‐Blind, Randomized, Placebo‐Controlled Trial of Levetiracetam as Add‐On Therapy in Patients with Refractory Partial SeizuresEpilepsia, 2000
- Pharmacokinetic profile of levetiracetamPharmacology & Therapeutics, 2000
- Double‐Blind, Placebo‐Controlled, Lamotrigine in Treatment‐Resistant Generalised EpilepsyEpilepsia, 1998
- The use of lamotrigine in juvenile myoclonic epilepsySeizure: European Journal of Epilepsy, 1996
- Proposal for Revised Classification of Epilepsies and Epileptic SyndromesEpilepsia, 1989
- Epilepsy with impulsive petit mal (Juvenile Myoclonic Epilepsy)Acta Neurologica Scandinavica, 1985